Medical Affairs

Somerville, NJ, United States

Medical Affairs

Somerville, NJ, United States
SEARCH FILTERS
Time filter
Source Type

Study finds 60% growth in pharmaceutical thought leader development activity between Phase 2 and Phase 3a RESEARCH TRIANGLE PARK, NC--(Marketwired - May 08, 2017) - Between both Phase 3a and 3b, 50% of surveyed teams begin their thought leader development activities, with the next most popular stage to begin these activities being registration and launch, according to new research published from pharmaceutical business intelligence provider Cutting Edge Information. The data published in Thought Leader Management: Medical Affairs Product Launch Series show that most surveyed medical affairs teams start after Phase 2 -- only 25% of surveyed teams start their thought leader development activities before Phase 3. Many drug and device companies do not start major thought leader development activities before Phase 3 due to the much higher failure rate of drugs in the earlier phases of the lifecycle. Data from the same study revealed that no surveyed medical affairs team began its key opinion leader (KOL) development after launch. "Thought leader development usually begins before or during launch to establish relationships with healthcare providers before the product is released," said Natalie DeMasi, research team leader at Cutting Edge Information. "Establishing a foundation with KOLs can increase the drug's success upon launch." Surveyed medical affairs teams start thought leader development activities depending on whether they are supporting niche or blockbuster products. None of the surveyed teams that released niche products begin their thought leader development activities in Phase 1, and only 20% start by Phase 2. A sharp 60% growth occurs in Phase 3a, and by Phase 3b, all surveyed niche product teams begin their KOL development activities. Additional data gathered show that surveyed blockbuster products participating in thought leader development activities reach 60% during Phase 3a and 3b, and reach 100% after a 40% growth from Phase 3b to registration and launch. Thought Leader Management, available at https://www.cuttingedgeinfo.com/product/thought-leader-management/, showcases innovative insights, best practices and benchmarks surrounding thought leader development activity start times, budgets, staffing, key performance indicators, and resources that occur as part of medical affairs' contributions to product launch strategy. In developing this research, Cutting Edge Information's analysts collected surveys from and consulted with medical affairs leaders at top pharmaceutical, biotechnology and medical device companies. Thought Leader Management is part of a 10-part series that Cutting Edge Information will be publishing throughout 2017. The Medical Affairs Product Launch Series, available at https://www.cuttingedgeinfo.com/product/medical-affairs-product-launch-series/, investigates how medical affairs resources and key performance indicators (KPIs) shift between two years prior to launch, one year before launch, launch year and during the product's first year on market. To learn more about medical affairs' involvement in thought leader development activity, please visit https://www.cuttingedgeinfo.com/product/thought-leader-management/ for more information.


In Dodson's most recent role, she led the alignment of Medical Affairs practices, policies and standards across the globe – including the launch of global systems to manage Medical Communications, Publications and Investigator Sponsored Research (ISR). During her time at Astellas, she has also expanded the Health Economics & Outcomes Research function and pioneered multiple, innovative real world data projects and research partnerships with leading managed care and academic organizations. In her new role, Dodson will report directly to Kremer and assume overall responsibility for the strategic direction of the Medical Affairs Americas organization, including continued medical support of in-line products, late-stage development compounds and ongoing business evolution across the region. Dodson has extensive clinical and research experience in the healthcare and pharmaceutical industries. After starting her career in direct patient care at the Department of Veterans Affairs, Dodson spent more than a decade at Pfizer in various Medical Affairs leadership roles spanning the urology and respiratory franchises. Following her work with Pfizer, Dodson then served as vice president of Medical Affairs at GTx, Inc., where she led a Phase 3 clinical development study of a selective androgen receptor modulator for the prevention and treatment of muscle wasting in patients with cancer. She also incorporated key economic and health outcomes assessments to support product utilization and valuation. Dodson has received multiple awards for leadership and innovation throughout her career, including the National Healthcare Business Women's Association Rising Star and the Astellas Vision Award. She earned a doctorate of pharmacy degree from Mercer University School of Pharmacy and completed a postdoctoral residency at the Department of Veterans Affairs Medical Center in Nashville, Tenn. About Astellas Pharma Inc. Astellas Pharma Inc., co-headquartered in Tokyo, Japan, and Northbrook, Ill., is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 18,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious diseases, Oncology, Neuroscience and Diabetes Mellitus (DM) Complications and Kidney diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-names-shontelle-dodson-senior-vice-president-and-head-of-medical-affairs-americas-300455329.html


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are being presented tomorrow at the American Urological Association (AUA) 2017 Annual Meeting in Boston, Mass. This study was conducted in collaboration with Stephen Bardot, M.D., and colleagues at Ochsner Clinic in New Orleans, Louisiana.  A total of 767 men with localized prostate cancer were evaluated using the Prolaris test plus CAPRA (i.e., clinical features) to predict the risk of metastatic disease up to 10 years following diagnosis.  Approximately 40 percent of the patients in the study were African Americans (AA).  Among all 767 patients 39 men, or 5.1 percent, developed metastases and among the 646 men who received definitive therapy (e.g., surgery, radiation, radiation and hormones) 28 men, or 4.3 percent, developed metastatic disease. The results showed that the Prolaris test was a significant predictor of metastatic disease with a nearly 3-fold increased risk for each one-unit increase on the Prolaris test score (Hazard Ratio per unit score = 2.76; P = 2.8x10-11).  Importantly, there was no difference in predictive performance between races (p=0.20) or treatment groups (p=0.09).  When combined with CAPRA the Prolaris test was highly predictive of metastatic disease (HR for combined clinical risk (CCR) = 3.86; p= 2.8x10-23).  Contrary to expectations, this large study found no evidence that AA men have more aggressive prostate cancer than non-AA men after accounting for all molecular and clinical information. “Our study confirmed that the Prolaris test significantly predicts which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach,” said Dr. Bardot.  “This study also included a large group of AA men which have historically been underrepresented in clinical outcomes studies.  This study demonstrated that Prolaris provided more accurate precision in providing prognosis in African American and non-African Americans equally.” The findings from the current study are consistent with the findings of an earlier study that demonstrated the ability of the Prolaris test in predicting cancer progression, as measured by both biochemical recurrence and metastatic disease, after radical prostatectomy. That prior study found that patients with a high Prolaris test score had a six-fold higher risk of developing metastases compared to low risk patients. Based on the strength of the data from these two outcomes studies, Myriad has added risk of metastases to the Prolaris test report for clinicians, making Prolaris the first and only genetic test to provide this endpoint as validated by two outcomes studies. “Myriad Genetics is committed to innovation and being the leader in genetic testing for men diagnosed with prostate cancer,” said Michael Brawer, M.D., senior vice president of Medical Affairs, Myriad Genetic Laboratories.  “We have multiple outcome studies that show the ability of Prolaris to predict the 10-year risk of prostate cancer specific mortality, and we now have two studies that predict the risk that treatment will fail and men will end up with metastatic disease.  We are excited to provide all of this relevant information in a single test report for clinicians.” Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #AUA17.  Details of the presentation at AUA follow. Featured Presentation Title: Evaluating the Prognostic Utility of the CCP Score for Predicting Prostate Cancer Aggressiveness in African American Men Presenter: Steven Bardot, M.D., Ochsner Medical Center Date: Saturday, May 13, 2017: 7:00-9:00 a.m. ET. Location: Moderated Poster MP28-19; Room 253AB. About Prolaris® Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease-specific mortality in patients with prostate cancer. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth.  Low gene expression is associated with a low risk of disease-specific mortality in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease-specific mortality in patients who may benefit from additional therapy.  For more information visit: www.prolaris.com. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement        This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Prolaris data being presented at the at the American Urological Association’s 2017 Annual Meeting being held May 12-16, 2017 in Boston, Mass.; the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer; the ability of the Prolaris test to significantly predict which men are likely to develop metastatic disease, regardless of race, risk group or treatment approach; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.


News Article | May 5, 2017
Site: www.chromatographytechniques.com

Researchers have identified a gene that plays a key role in the formation of neural tube defects, a problem commonly found in infants of pregnant women with diabetes. This is the first time the gene has been shown to play this role; it opens up a new way to understand these defects, and may one day lead to new treatments that could prevent the problem or decrease its incidence. The findings were published today in the journal Nature Communications. "This gene plays a crucial role in the process that leads to these defects," said the study's lead author, Peixin Yang, a professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at UM SOM. "Now that we have pinpointed the mechanism, we can begin to focus on how we can stop it from happening in humans." Neural tube defects (NTDs) occur when mutations accumulate in the neuroepithelial cells, neural stem cells that eventually transform themselves into the brain and the central nervous system. the problem occurs after the fetus is exposed to too much glucose, which can cause widespread cell death, eventually leading to the birth defects. The researchers focused on a gene called Prkca, which plays a key role in regulating autophagy, the process by which cells dispose of material they no longer need; often this material is broken or flawed in some way. In diabetes, the Prkca gene becomes overactive, and as a result autophagy is suppressed. As a result, the flawed cellular material is used to create embryonic tissue, which can lead to major birth defects. In essence, the process is a series of dominoes. The Prkca gene triggers production of a protein called protein kinase C-alpha, or PKCalpha. PKCalpha in turn increases expression of a molecule called miR-129-2, which decreases the levels of a protein called PGC-1alpha, which encourages the destruction of flawed cells. In an experiment using pregnant diabetic mice, Dr. Yang and his colleagues deleted this gene, which allowed autophagy to work normally. In animals in which the gene had been deleted, embryos had far fewer NTDs. The scientists also examined whether it is possible to reduce NTDs by restoring the expression of PGC-1alpha in developing neural cells. During diabetic pregnancy, PGC-a1alpha re-activated the process of destroying flawed cells and also reduced the death of normal cells. This reduced levels of NTDs. Yang says that in the future it may be possible to prevent and TDs in humans by using medicines that inhibit PKCalpha or miR-129-2, or activate PGC-1alpha. Neural tube defects are birth defects of the brain and spinal cord. They occur in the first month of pregnancy. The two most common are spina bifida and anencephaly. In the first, the fetal spinal column doesn't close completely. This usually causes nerve damage, with some paralysis of the legs. In the latter, most of the brain and skull do not develop. Infants with this defect are usually stillborn or die soon after birth. Neural tube defects have several causes, including diabetes, folic acid deficiency, obesity in the mother, and consumption of certain medications. About 10 percent of women with diabetes who are pregnant will have embryos with neural tube defects. Globally more than 300,000 pregnancies are affected by NTDs every year. One out of ten babies with NTDs die before their first birthday. In the US alone, medical and surgical costs for children born with NTDs come to more than $200 million a year. Pregnant women who have diabetes have a significantly higher risk of having a child with NTDs, and even with the highest quality preconception care, diabetic women are five times more likely to have a child with birth defects than are non-diabetic women. The researchers on the article include UM SOM Dean E. Albert Reece, MD, PhD, MBA. "Neural tube defects remain a significant hazard for pregnant women who have diabetes," said Dean Reece, who is also the vice president for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor. "Women with diabetes prior to pregnancy are between three and 10 times more likely to have a child with NTDs than women without disease. This new research shines a fresh light on how we can continue to reduce this urgent problem."


CULVER CITY, Calif.--(BUSINESS WIRE)--NantCell and NantKwest Inc. (NASDAQ:NK), two pioneering, next generation, clinical-stage immunotherapy companies focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the U.S. Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) Application for the NANT Cancer Vaccine for clinical trial enrollment for pancreatic cancer patients (ClinicalTrials.gov NCT03136406). The NANT Cancer Vaccine is the first combination immunotherapy protocol to orchestrate the delivery of metronomic low-dose radiation and chemotherapy with molecularly-informed, tumor-associated antigen vaccines and natural killer cells, to activate the innate and adaptive immune system and to induce immunogenic cell death. By inducing immunogenic cell death and protecting as well as enhancing the innate and adaptive immune system, the NANT Cancer Vaccine seeks to attain long-term sustainable remission of multiple tumor types with lower toxicity and higher efficacy than current standards of care. “Abraxane, a nanoparticle albumin-bound (Nab) paclitaxel, was the first protein-based drug to alter the survival of metastatic pancreatic cancer in over 20 years,” noted Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest. “But we were not content just with the approval of Abraxane as being sufficient to transform this disease. In January 2016, we announced our Cancer Breakthroughs 2020 journey towards developing effective personalized cancer treatments to further harness the human body's innate immune system as a paradigm change to treating patients with cancer. Today's FDA clearance is a further step in our 25-year quest to develop this cancer vaccine that seeks to induce immunogenic cell death and orchestrate the innate and adaptive immune system of the patient through the delivery of molecularly informed, biological platforms. To our knowledge this is the first clinical study whereby protein nanoparticles (Nab) delivering low dose metronomic chemotherapy is combined with molecularly informed (GPS Cancer) tumor associated antigens activating dendritic and T cells by adenoviral and yeast vectors, and orchestrated with both endogenous (IL-15) and exogenous (off the shelf) activation of NK cells. This NANT Cancer Vaccine will be studied in patients suffering from all types of cancers and at all stages of disease in the coming 12 months, a Cancer Breakthroughs 2020 goal," Dr. Soon-Shiong added. “Cancer has historically been one of the most complex challenges that the medical community has tried to combat,” said John Lee, MD, FACS, Senior Vice President of Clinical Development at NantKwest. “Receiving authorization from the FDA for the IND application for the NANT Cancer Vaccine is a testament to our novel immunotherapy approach. Today marks an important milestone for cancer care and reinforces the need for a paradigm shift in the way we approach this deadly disease. NantKwest and NantCell are actively working to initiate the clinical trial across investigational centers and we look forward to offering the NANT Cancer Vaccine regimen to pancreatic cancer patients.” “Cancer cells often go undetected by the immune system; recently, it was found that cancer cells place a brake on the immune system by checkpoint receptors. This discovery has brought forth a new revolution of immuno-oncology with the launch of multiple checkpoint inhibitors. We realize, however, that checkpoint inhibition alone is insufficient to fully activate the immune system to combat the cancerous tumor,” stated Leonard S. Sender, M.D., Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology at NantKwest. “NANT Cancer Vaccine is a unique, multi-agent protocol aimed at orchestrating all the components of the immune system needed to combat cancer.” This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning or implying the timing and conduct of our clinical studies, the anticipated safety and efficacy of our NK cell therapy and the accomplishment and timing of related regulatory determinations and filings. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks and uncertainties include, but are not limited to, the rate of subject enrollment in our clinical studies; the number of subjects that will need to be enrolled in the trial; difficulty obtaining and maintaining regulatory approvals; our limited experience in conducting clinical studies and significant issues regarding our clinical studies, including, but not limited to, the successful opening and the continued participation of clinical sites and their ongoing adherence to protocols, assumptions regarding enrollment rates, timing and availability of subjects meeting inclusion and exclusion criteria, changes to protocols or regulatory requirements, the ability to comply with and meet applicable laws and regulations, unexpected adverse events or safety issues and the sufficiency of funding and adverse events affecting our ability to manufacture and supply cell therapy for our clinical studies. There can be no assurance that data from any of our clinical studies will be sufficient to support an application for marketing in any country or that any such application will ever be approved. These and other risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. These forward-looking statements speak only as of the date hereof, and NantKwest, Inc. disclaims any obligation to update these statements except as may be required by law. The NANT Cancer Vaccine is the first combination immunotherapy protocol to orchestrate the delivery of metronomic low dose radiation and chemotherapy with molecularly informed tumor associated antigen vaccines and natural killer cells, to activate the innate and adaptive immune system and to induce immunogenic cell death. By inducing immunogenic cell death and protecting as well as enhancing the innate and adaptive immune system, the NANT Cancer Vaccine seeks to attain long-term sustainable remission of multiple tumor types with lower toxicity and higher efficacy than current standards of care. NantKwest (NASDAQ:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Chimeric Antigen Receptor (CAR) activated killing using taNKs, which are NK cells engineered to incorporate CARs to target tumor-specific antigens found on the surface of cancer cells. Our aNK, haNK® and taNK TM platform addresses certain limitations of T cell therapies including the reduction of risk of serious “cytokine storms” reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest’s NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest’s NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. For more information please visit http://www.nantkwest.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong. NantCell, a wholly-owned subsidiary of NantWorks, LLC, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of the patient's tumor, independent of the cancer's anatomical type. NantCell's mission is to make obsolete the standard method of clinical trial design of "trial and error" and replace it with a level of quantitative predictability based on both the genomic and proteomic profile performed a priori. The Company will tap into comprehensive “omic” analytic tools and "big data" generated from supercomputing to develop molecularly designed drugs in this era of genomics and proteomics and identify patients and their tumor signature at the most granular cellular, DNA and protein levels. Patients entering clinical trials would be identified after a comprehensive “omic” analysis from tissue to cell to DNA to RNA to protein to peptide to drug, and tested based on this molecular profile to maximize clinical outcome and minimize side effects. Through these integrated diagnostic methods, the company is pursuing the vision of treating the biology of cancer rather than the anatomy, and driving the immune system inherited by all to defeat cancer. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong. NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

Loading Medical Affairs collaborators
Loading Medical Affairs collaborators